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increased the resting release by two to six times. These effects indicate an inhibitory action of these anaesthetics on Na + -and K + -channels. There was no difference in clinically important nerve conduction between non-diabetic and diabetic rats, as measured by the release of transmitter in response to axonal stimulation. The uptake and resting release of NA was significantly higher in the brain slices prepared from diabetic rats, but there were no differences in the spinal cord. For the adverse effects, the effects of articaine on K + channels (resting release) are more pronounced compared to lidocaine. In this respect, articaine has a thiophene ring with high lipid solubility, which may present potential risks for some patients.
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Introduction
Diabetes mellitus (DM) is characterized by hyperglycaemia that is induced by defects in insulin secretion from pancreatic β-cells and/or the effects of insulin on target cells. After cardiovascular disease, DM is the third leading cause of death in the US, Europe [32] and Hungary [16, 31] . It has been shown that the risk of neurotoxicity is higher in patients with diabetic peripheral neuropathy, which is a critical finding for clinicians who are involved in dental care or who apply local anaesthetics for surgery or for short-and long-term pain management.
All local anaesthetics that can inhibit both Na + and K + -channels [25] are potentially neurotoxic, as is the case for articaine [2, 6] , which is a widely used anaesthetic in dental care [27] . The inhibitory effects of these anaesthetics on Na + channels are responsible for the local anaesthetic effect [18, 20, 21] , whereas the inhibition of K + channels leads to adverse [35] effects. Patients with diabetes may have peripheral neuropathy, which may have clinical implications for the use of regional nerve blocks. There is agreement among researchers that the prevalence and severity of periodontal diseases are greater in individuals with diabetes [22, 24] . Therefore, it is essential to be familiar with the possible complications that may occur during the treatment of diabetic patients.
Articaine is similar to lidocaine, and its use in clinical practice has shown that it is suitable and safe for clinical interventions that require a short duration and fast onset of action in dental practice and ambulatory spinal anaesthesia [1, 27] . Although it has been shown that the risk of neurotoxicity with local anaesthetics is relatively small, there are still concerns about the safety of their use [4, 26] , especially among diabetic patients [19] .
In previous studies [5, 26] , we showed that lidocaine and bupivacaine, due to their actions on Na + channels, inhibited the release of transmitters from frontal cortex and spinal cord slices in response to ongoing axonal activity and strongly enhanced the resting release induced by the inhibitory effects on K + channels. The effect on Na + channels was similar to that of tetrodotoxin, a selective Na + channel blocker, and the effect on K + channels was the same as that evoked by 4-aminopyridine, which is a selective K + channel blocker [26] . Accordingly, in this study, we tested the effects of articaine on these two types of release using cortical and spinal cord slice preparations taken from non-diabetic and streptozotocin (STZ)-induced diabetic rats and compared them with the effects of lidocaine.
Materials and methods

Animals
The experiments were carried out on male Wistar rats (200-300 g body weight). The rats were kept in cages with a mesh bottom placed over a metal plate lined with ground corn cob bedding, at room temperature (20 ± 2 °C) with relative humidity (60-70%) and a 12/12 h light/dark cycle. Rats were fed standard rodent food pellets and water ad libitum. 
Streptozotocin (STZ) treatment
An intraperitoneal (i.p.) injection of STZ (60 mg/kg) at 2.5 ml/kg body weight was given as described previously [8, 11] . The STZ solution was made by dissolving 60 mg/2.5 ml cold distilled water (1-3°C) in a relatively dark place prior to the injections and was used within 10 min to avoid any degradation. The age-matched control rats were injected with an equal volume of cold distilled water at the same temperature.
Blood glucose level measurements
Blood glucose level was measured 1 day prior to and 1 week following streptozotocin injection and after animal sacrifice on the day of the experiment. Briefly, the animals were slightly anaesthetized with 3% isoflurane in oxygen via a nose cone using a vaporizer (Eickemeyer Isoflo Vaporiser; Eickemeyer Veterinary Equipment Inc.). A small amount of blood (50 µl) was taken from rat tail veins and immediately placed on the test strip. The blood glucose was measured by an Accu-Chek Active blood glucose meter (Roche Diagnostics GmbH, Germany). The maximum measurable blood glucose level that could be detected in the applied test is 33.3 mmol/l. The animals were considered diabetic if the blood glucose concentration was higher than 14 mmol/l.
Nociceptive test (assessment of neuropathic pain)
Mechanical allodynia was determined on the day prior to STZ treatment and on the 3 rd , 6 th and 9 th weeks after STZ treatment. Briefly, a metal filament with a 0.5 mm diameter was applied to the plantar surface of the animal paw. The threshold of hind paw withdrawal was determined using a Dynamic Plantar Aesthesiometer (DPA) (Ugo Basile, Italy) as described previously [9, 28] . Animals were placed in plastic cages with a perforated metal platform floor for the DPA once a day for 3 days ("handling") before STZ treatment. Animals were kept in these cages for at least 5 minutes before starting the measurement to habituate them.
Increasing force was initiated when the tip of the metal filament touched the plantar surface of the rat's hind paw. The force was automatically set, and 50 grams was the cut-off. The withdrawal threshold was measured and expressed in grams before and at the 3 rd , 6 th and 9 th weeks after STZ treatment. The withdrawal threshold was determined alternately in each paw three times, and the average of the measurements was recorded for each animal. The animals were grouped as follows: control (weight-matched) group (n=8), non-diabetic (vehicle treated) and diabetic rats (n=11).
Tissue preparation
Frontal cortex slices were prepared from the prefrontal cortex (PFC) as described previously [3] .
Caudal spinal cord segments L5-S1 were prepared using a previously described technique [5, 30] . Spinal cord segments were removed and placed into ice-cold modified Krebs solution of the following composition (mmol/l): NaCl, 113; KCl, 4.7; CaCl2, 2.5; KH2PO4, 1.2; MgSO4, with Minipuls 3 multi-channel peristaltic pump (Gilson Inc., Middleton, WI, USA) at 37 °C at a rate of 0.7 ml/min for 60 min with Krebs solution and continuously bubbled with carbogen and the effluent used for washing was discarded. During the experiment, the effluent was collected in 3-min fractions, and the radioactivity was measured. The preparations were stimulated via platinum electrodes using a Grass S88 stimulator (Astro-Med Inc., West Warwick, RI, USA). For PFC slices, supramaximal (20 V) field stimuli of 2-ms pulse durations were applied at 2 Hz for 90 s ( 180 shocks). For spinal cord slices, supramaximal (40 V) field stimuli of 1-ms pulse duration were applied at 3 Hz for 80 s ( 240 shocks). This type of stimulation excited noradrenergic axons and resulted in release of NA in a tetrodotoxine-sensitive manner [34] . The amount of the release induced by the first stimulation (S1) was used as an internal standard. Local anaesthetics were applied 21 min before the second stimulation (S2) was applied to the preparations and kept in the solution continuously afterwards. After the fractions were collected, 0.5 ml of each perfusate solution was mixed with 2 ml of liquid scintillation cocktail. The radioactivity was determined as described in the following section.
At the end of the experiments, tissues were homogenized in 0.5 ml of 10% trichloroacetic acid for 30 min. Aliquots (500 µl) of the superfusate and aliquots (100 µl) of the tissue supernatant were added to 2 ml of Packard Ultima Gold scintillation cocktail. Released (fractions 3-6 and 13-16) was considered to be the release due to neuronal activity (FRS1 and FRS2). The release in the two subsequent consecutive fractions (7-8 and 17-18) was considered the resting release.
Statistical analysis
Radioactivity values corresponding to [ 3 H]NA uptake and release were statistically analysed using one or two-way ANOVA with Graphpad-Prism 7.0 statistical software. The data are presented as the means ± SEM. A p value < 0.05 was considered statistically significant.
Results
Streptozotocin-induced neuropathic pain in diabetic rats
The rats treated with streptozotocin became diabetic (blood glucose level were > 14 mmol/l) (Fig. 1A) and displayed pronounced tactile allodynia (Fig. 1B) , as indicated by a significant decrease in paw pressure thresholds (unpaired t-test, p < 0.05). The peak of allodynia was achieved 9 weeks after STZ treatment (Fig. 1B) . The paw pressure threshold was (g) 40.88 ± 2.74 (n = 7) for non-diabetic rats and 32.02 ± 1.95 (12) for diabetic rats.
Uptake and release of [ 3 H]NA measured in PFC and spinal cord slices prepared from non-diabetic and diabetic rats
In 19 experiments, the PFC slices prepared from non-diabetic rats contained 354.90 ± 21.41 kBq/g radioactivity after 45 min of loading with [ 3 H]NA and subsequent washing ( Table 1) .
Over a 3-min collection period at rest, the average release from the PFC slices was 4.02 ± 0.46 kBq/g (1.24 ± 0.14% of the total radioactive content, n = 19). In response to electrical field stimulation, the release (S1) was 10.87 ± 1.24 kBq/g (n = 19), which was 2.63 ± 0.29%
of the radioactivity present in the PFC tissue at the time of stimulation. When we compared the uptake and resting release of [ 3 H]NA measured in non-diabetic and diabetic brain slices, a significantly higher amount of [ 3 H]NA was taken up by the slices prepared from diabetic rats (Table 1) . Similarly, the release at rest was higher in diabetic preparations (Table 1) .
However, there was no significant difference in stimulation-evoked releases.
After the tissue had been loaded, the average uptake of radioactivity in the spinal cord slices from the control (non-diabetic) group was 235.0 ± 15.2 kBq/g ( Table 2 , n = 24), and failed to differ from uptake measured in diabetic rats ( Table 2 , n = 48). The average resting release was 3.11± 0.18 kBq/g, 1.69 ± 0.09% of the total radioactivity content of the tissue (FRR1) (n=24) and was not significantly different from the release measured in diabetic slices. In response to electrical stimulation (S1), the release was 5.31±0.46 kBq/g, 2.65 ± 0.18% (n =24) of the total radioactivity present in the slices.
Effects of articaine and lidocaine on [ 3 H]-NA release from PFC and spinal cord slices prepared from non-diabetic and diabetic rats
The effects of articaine compared to lidocaine on [ 3 H]NA release from PFC (Table 1) and spinal cord slices (Table 2) at various concentrations (0.3-10 mM) (Table 3) were studied and were likely reached following injection into the tissue. In PFC preparations at rest, 0.7 ± 0.05% of the radioactive content was released during the 3-min collection period. The change in resting release over a 30-min period was always compared to the control value (FRR1), determined during the 3-min collection period (FRR2/FRR1 = 0.87 ± 0.06, n = 6) ( Fig. 2A) . In samples that underwent electrical field stimulation, [ 3 H]NA was released (S1 = 7.4 ± 0.9 kBq/g, n = 6), and the FRS2/FRS1 was 0.84 ± 0.09 (n = 6). At a concentration of 3 mM, articaine resulted in a four-fold increase in the resting release (Fig. 2C) , whereas lidocaine resulted in a two and a half-fold (Fig. 2B ) increase. While 3 mM articaine completely blocked the stimulation-evoked release (Fig. 2C) , lidocaine only reduced this release. However, 10 mM of lidocaine completely blocked the stimulation-evoked release and enhanced the resting release by more than five times (Table 3 ). Articaine at the 0.3 mM concentration induced a significant 1.4-fold increase in resting release and failed to reduce the stimulation-evoked release. No differences were observed in the effects of local anaesthetics on the resting release measured in non-diabetic and diabetic slices; both conditions enhanced the release to the same extent ( Table 2 ).
In spinal cord slices, both lidocaine and articaine significantly increased the resting release (Table 2 , Fig. 2 B and C, Fig. E and F) , and their effects on the release of NA from slices prepared from non-diabetic and diabetic animals differed.
Discussion
In dental care and during spinal and epidural anaesthesia, the neurons are exposed to relatively high concentrations of local anaesthetics that diffuse directly into the tissue [4] and beside their therapeutical action may cause adverse effects. Since a significant proportion of diabetic patients have clinical or subclinical neuropathy, there may be concerns about the use of local anaesthetics. For epidural anaesthesia and in dental care, local anaesthetics are applied at concentrations of 1.5 -2% (lidocaine, 55.2-69.25 mM) or 1-4% (articaine, 31.41-124.67 mM) for dental analgesia [13] . Therefore, the present study was designed to determine and compare the effects of articaine and lidocaine on the resting and axonal stimulationevoked release of [ 3 H]NA in prefrontal cortex and spinal cord slices prepared from nondiabetic and streptozotocin-induced diabetic rats. We failed to observe differences between the axonal stimulation-evoked releases measured in slices obtained from non-diabetic and diabetic rats. These findings indicate that there is no impairment in nerve conduction. The uptake and resting release of NA were higher in brain slices prepared from diabetic rats but not in preparations obtained from the spinal cord. Any inhibitory effect of local anaesthetics on the release of transmitter from nerve terminals in response to axonal activity or an increase in release at rest (defined as when there is no axonal firing) indicates a Na + -channel-or K + -channel-dependent action. The former effect results in conduction blockage and numbing of pain, and the latter effect may produce adverse reactions.
It should be mentioned that in clinical studies investigating local anaesthetics, an increased duration of sensory block in diabetic vs control patients was observed [10] . These findings are consistent with the results observed in rats [17, 19] . When the therapeutic efficacy of articaine was compared [27] to that of other local anaesthetics (lidocaine, prilocaine and chloroprocaine), the studies failed to show any evidence of clinical advantages of any anaesthetic over another.
Our findings with articaine and lidocaine administered at concentrations of 0.3-3 mM were that the stimulation-evoked releases were inhibited in a concentration-dependent manner, with the resting release increasing by two to six times (Table 3) , depending on the concentration applied. This indicated the inhibitory action of these anaesthetics on Na + -and K + -channels (Figs. 3A-D) . In clinical practice, these concentrations were easily reached and could inhibit both the Na + and K + channels. As far as adverse effects are concerned, the effects on K + channels seem to be more important. The inhibitory effects on K + channels result in the release of large amounts of transmitters, including NA and glutamate, into the extracellular space, where their metabolites (DOPAL and DOPEGAL) [7] and glutamate itself could be neurotoxic. In this respect, articaine has a thiophene ring with high lipid solubility [27] , which may confer a potential risk for some patients. Neurotoxic injuries have been reported after local anesthetics, in humans even an overrepresentation of neurosensory disturbance associated with 4% formulations of articaine used in dentistry [12] . In addition a concentration-dependent neurotoxicity was show in animal experiments after 4% rather than 2% of articaine [15] . However, articaine does display an advantage of negligible cardiotoxic effects compared to other local anaesthetics [29] .
The intrathecal and epidural administration of 2-adrenoceptor agonists (e.g. clonidine) are widely used for spinal analgesia for intrectable pain [23] . Accordingly, the NA-releasing effect of anesthetics (lidocaine and bupivacaine, [5, 26] and articaine (this paper) may be involved in their pain killing effects.
Epidural infusion of local anesthetic alone may be applied for postoperative analgesia. It has been shown, that articaine (50 mg) used for spinal anesthesia [1] for knee arthroscopy [14] migh result in more than 2 mM concentration in lumbo sacral cerebrospinal fluid ( 60 ml). In our experiments articaine (inhibited NA release in response to field stimulation) produces a complete block of nerve conduction, but also results in high ambient concentration of NA in the extraneuronal space, therefore we conclude, that NA released by anesthetics are involved in their pain-killing effects via stimulation of 2-adrenoceptors.
Our findings may have implications for the appropriate dosages of local anaesthetics in diabetic patients undergoing regional analgesia with nerve blocks either in dental treatment or in spinal anaesthesia.
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